609-55-2

Usage

Uses

Used in Pharmaceutical Industry:
2-amino-5-methylbenzenesulfonamide is used as a pharmaceutical intermediate for the synthesis of sulfonamide drugs, which are known for their antibacterial properties. It plays a crucial role in the development of medications that combat bacterial infections.
Used in Urinary Tract Infections Treatment:
In the medical field, 2-amino-5-methylbenzenesulfonamide is being studied for its potential use in treating urinary tract infections. Its antibacterial properties make it a promising candidate for this application.
Used in Antitumor Agent Development:
2-amino-5-methylbenzenesulfonamide is also being investigated for its potential in the development of antitumor agents. Its properties are being explored to contribute to the creation of medications that can help in the fight against cancer.
Safety Precautions:
It is important to handle 2-amino-5-methylbenzenesulfonamide with care, as it may be harmful if ingested or inhaled, and can cause skin and eye irritation. Proper safety measures should be taken during its use to minimize any potential risks.

InChI:InChI=1/C7H10N2O2S/c1-5-2-3-6(8)7(4-5)12(9,10)11/h2-4H,8H2,1H3,(H2,9,10,11)

Upstream product

• 55825-29-1 2-amino-4-chloro-5-methyl-benzenesulfonamide 
• 71254-63-2 7-methyl-3-oxo-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide 
• 380885-39-2 N-(p-toluenyl)-N'-(chlorosulfonyl)-urea 
• 106-49-0 p-toluidine 
• 855941-97-8 4-acetylamino-toluene-3-sulfonic acid amide 

Downstream Products

• 477932-77-7 N-(4-methyl-2-sulfamoyl-phenyl)-malonamic acid ethyl ester 
• 1161943-44-7 2-[[(E)-2-(4-Bromophenyl)ethenyl]sulfonylamino]-5-methyl-benzenesulfonamide 
• 1161942-84-2 2-[2-(4-chloro-phenyl)-ethanesulfonylamino]-5-methylbenzenesulfonamide 
• 1161944-02-0 2-(2,3-Dichloro-benzenesulfonylamino)-5-methyl-benzenesulfonamide 
• 1161945-06-7 2-(3-bromobenzenesulfonylamino)-5-methyl-benzensulfonamide 
• 1161944-38-2 2-(2-(4-Bromophenyl)ethylsulfonamido)-5-methylbenzenesulfonamide 
• 1190590-28-3 5-[4'-(2-sulfonamido-(4'-methyl)-phenyl aminoethoxy)benzylidenyl]-2,4-thiazolidinedione 
• 1190590-29-4 5-[4'-(2-sulfonamido-(4'-methyl)-phenyl aminoethoxy)-3'-methoxybenzylidenyl]-2,4-thiazolidinedione 
• 1190590-30-7 5-[4'-(2-sulfonamido-(4'-methyl)-phenyl aminoethoxy)-3',5'-dimethoxybenzylidenyl]-2,4-thiazolidinedione 
• 635702-64-6 pazopanib hydrochloride 
• 153439-24-8 C₁₁H₁₄N₂O₅S 
• 1432503-58-6 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-methyl-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-60-0 methyl 2-(7-methyl-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1392210-38-6 C₁₇H₁₆BrFN₂O₄S 

Relevant academic research and scientific papers

Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase

The development and progression of chronic complications in diabetic patients, such as retinopathy, nephropathy, neuropathy, cataracts, and stroke, are related to the activation and/or overexpression of aldose reductase (ALR2), which is a member of the al

Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1- benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells

N-(2,2-Dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2, 4-benzothiadiazine-3-carboxamides 1,1-dioxides were prepared and evaluated on rat uterus, rat aortic rings and rat pancreatic β-cells. Pharmacological studies conducted on rat uterus indicated that several of these original hybrid compounds displayed a strong myorelaxant activity. The most active compounds hold a bromine atom at the 6-position of the dihydrobenzopyran ring. Moreover, the compounds failed to display a marked inhibitory effect on insulin secretion and vascular myogenic activity. These features suggest that the 6-bromo compounds could be relatively selective towards the uterine smooth muscle.

METHODS FOR IDENTIFICATION OF JAK KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF JAK KINASES

The present invention relates to immobilization compounds and methods useful for the identification of JAK interacting compounds or for the purification or identification of JAK.

Bis-(Sulfonylamino) Derivatives in Therapy 205

The invention provides compounds of formula (I) wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmac

Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.